Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EBITDA (2016 - 2025)

Integra Lifesciences Holdings' EBITDA history spans 17 years, with the latest figure at $23.0 million for Q4 2025.

  • For Q4 2025, EBITDA fell 35.33% year-over-year to $23.0 million; the TTM value through Dec 2025 reached -$496.1 million, down 99325.65%, while the annual FY2025 figure was -$493.4 million, 1836.55% down from the prior year.
  • EBITDA for Q4 2025 was $23.0 million at Integra Lifesciences Holdings, up from -$6.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $75.8 million in Q1 2021 and bottomed at -$490.9 million in Q2 2025.
  • The 5-year median for EBITDA is $25.9 million (2021), against an average of $1.1 million.
  • The largest annual shift saw EBITDA skyrocketed 2523.93% in 2021 before it plummeted 2296.61% in 2025.
  • A 5-year view of EBITDA shows it stood at $58.2 million in 2021, then grew by 16.52% to $67.8 million in 2022, then tumbled by 46.86% to $36.0 million in 2023, then fell by 1.17% to $35.6 million in 2024, then tumbled by 35.33% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for IART's EBITDA are $23.0 million (Q4 2025), -$6.5 million (Q3 2025), and -$490.9 million (Q2 2025).